AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00946023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Start on Day 5 through Day 180
Study NCT00946023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
Study NCT00946023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Day 30 and every week after for 8 total doses: 375 mg/m\^2 IV
Study NCT00946023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplant (BMT)
Description: Day 0: Donor bone marrow infusion
Study NCT03310905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Wall Transplant with another solid organ transplant
Description: Transplant of abdominal wall in combination with another solid organ transplant.
Study NCT03310905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Wall Transplant alone
Description: Abdominal Wall Transplant alone
Study NCT02614586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058 Placebo
Description: TAK-058 placebo-matching, solution.
Study NCT03357770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature \[5\]. The low-dose is 1 × 10\^7cells / 3mL, the medium-dose is 5 × 10\^7cells / 3mL and the high dose is 1 × 10\^8cells / 3mL
Study NCT03064269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
Study NCT01598207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marinol
Description: 5mg BID, orally for 1 month
Study NCT01598207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg BID, orally for 1 month
Study NCT04176718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: predetermined dose, intravenously, at predetermined times per cycle
Study NCT04176718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: predetermined dose, intravenously, give 3 times per cycle
Study NCT04176718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: predetermined dose, orally, daily per cycle
Study NCT04176718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: predetermined dose, orally, given 8 times per cycle
Study NCT04280484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Hypoxia
Description: 1 minute of 9% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
Study NCT04280484 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Hypoxia
Description: 1 minute of 21% oxygen in the inspired air, alternating with 1 minute of 21% oxygen; for a total of 15 iterations/episodes.
Study NCT04127461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic endoscope
Description: The endoscope is a minimally invasive tool used to remove veins from the leg traditionally used for CABG.
Study NCT04127461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic endoscope
Description: The endoscope is a minimally invasive tool used to remove veins from the leg traditionally used for CABG.
Study NCT02152982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02152982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02152982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT02152982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02152982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02152982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02152982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study NCT02614586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Placebo
Description: Ondansetron placebo-matching, capsule.
Study NCT02817750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)
Description: zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
Study NCT02817750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)
Description: zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
Study NCT00520936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 1910 milligrams per meter squared (mg/m\^2) (or 60 milligrams per kilogram \[mg/kg\] if patient \<12 months old), intravenous (IV), for 21 days x 17 cycles
Study NCT03604380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Plasticity-Based Adaptive Cognitive Training
Description: Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
Study NCT03604380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
Study NCT01996293 — intervention group
Intervention type: DRUG
Intervention: lamotrigine
Description: Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
Study NCT01523353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: 4 week personalised exercise program on a static cycle. Supervised in a hospital environment
Study NCT02123121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol 1000 mg/day
Description: Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
Study NCT02123121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol 1500 mg/day
Description: Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
Study NCT02123121 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable cellulose
Description: Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
Study NCT02123121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All groups
Description: All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
Study NCT02123121 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: All groups
Description: All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
Study NCT04348773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: Dehydration of the natural tooth by tooth isolation
Study NCT04348773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehydration
Description: Rehydration
Study NCT00763672 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transmission of sFlt-1 results to the investigator
Description: Transmission of sFlt-1 results by the laboratory to the investigator
Study NCT00763672 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No transmission of the sFlt-1 results to the investigator
Description: The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
Study NCT02250170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-111077
Description: Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on \& 3 days-off (21 days=1cycle)
Study NCT03817788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Description: All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For polyethylene glycol group (group P): the day before colonoscopy, 750 mL (1 box) of polyethylene glycol solution should be drunk 2 hours after dinner; the other 1500 ml (2 boxes) of polyethylene glycol solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same juniar clinician, and related indicators were recorded.
Study NCT03817788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phosphate
Description: All patients should receive dietary guidance, and eat a low-residue diet three days before colonoscopy. For sodium phosphate group (group S), 750 mL (1 box) of sodium phosphate solution should be drunk 2 hours after dinner; and the other 750 mL (1 box) of sodium phosphate solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same clinician, and related indicators were recorded.
Study NCT03222960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propolis-containing toothpaste
Description: participants will use propolis-containing toothpaste for 6 months
Study NCT03222960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride-containing toothpaste
Description: participants will use Fluoride-containing toothpaste for 6 months
Study NCT00541593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic Pseudocystgastrostomy
Description: An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
Study NCT00351806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erigeron breviscapus injection
Study NCT00351806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hua tuo zai zao wan (a herbal medicine pill)
Study NCT00351806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound stroke herbal medicine (8 herbal)
Study NCT02050451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Plus®
Study NCT02050451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Study NCT05058118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FL058
Description: 50mg、250mg、500mg、1000mg、1500mg、2000mg
Study NCT05058118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: empty bottle
Study NCT00797706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHRONSEAL
Description: Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
Study NCT00797706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CHRONSEAL
Description: Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
Study NCT00655304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prometheus (R) liver support dialysis
Description: 6-8 hours of dialysis
Study NCT00655304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CVVHDF (Continuously Veno-Venous Hemodiafiltration)
Description: 6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
Study NCT04617106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery cannulation
Description: cannulation of Radial artery using standard IV cannula (axillary drug port will be taped using opaque adhesive)
Study NCT04013165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.
Study NCT04013165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Village-based intervention
Description: 1. Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~2. Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults.
Study NCT01655940 — intervention group
Intervention type: DEVICE
Intervention: Somanetics cerebral oximeter
Description: Somanetics cerebral oximeter
Study NCT01655940 — intervention group
Intervention type: DEVICE
Intervention: CASMED cerebral oximeter
Description: CASMED cerebral oximeter
Study NCT00560794 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab (MT103)
Description: Administered by continuous intravenous (CIV) over 4 weeks per cycle
Study NCT03879954 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Catetherization approach
Description: Out of plane inetrnal jugular vein Vs in plane supraclavicular subclavian vein catetherization
Study NCT02092467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: Oral tablet, 10 mg BID
Study NCT02092467 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Pre-filled syringe, 40 mg subcutaneous injection, every other week
Study NCT02394262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Coronary CT-angiography
Description: Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
Study NCT02394262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assesment of biomarkers involved in atherothrombosis
Description: Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
Study NCT03702985 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Pelvic Radiation: 50Gy/25Fx
Study NCT03702985 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Pelvic Radiation: 50Gy/25Fx
Study NCT03702985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625mg/m2 bid Monday-Friday per week
Study NCT03702985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 625mg/m2 bid Monday-Friday per week
Study NCT03702985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
Study NCT03702985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7)
Study NCT03702985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: 400mg/m2 per week
Study NCT02241629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo of levo phencynonate hydrochloride
Study NCT02241629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo of levo phencynonate hydrochloride
Study NCT02241629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levo phencynonate hydrochloride
Description: levo phencynonate hydrochloride
Study NCT00598104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576
Study NCT04437810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: - Patients in the Albumin Arm will receive Human Albumin 20% 1.5g/kg body weight (Maximum 100g) within 6 hours from the time of diagnosis over a period of 12 hours, followed by 1g/kg bodyweight (Maximum 100g) over a period of 12 hours after 48 hours of diagnosis.(D3)
Study NCT04437810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: standard medical therapy
Study NCT04437810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Medical Treatment
Description: standard medical therapy
Study NCT03157843 — intervention group
Intervention type: DRUG
Intervention: low-molecular-weight heparin
Study NCT03647748 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: A modified device utilizing a pigtail connector to bypass active treatment.
Study NCT00880607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: Morphine injection is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain.
Study NCT00880607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Epidural Morphine
Description: DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
Study NCT00196807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient decision aid (print-based)
Description: To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
Study NCT00196807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient decision aid (print-based)
Description: To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
Study NCT00789724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: 100 mg daily subcutaneous injection for 14 days
Study NCT00789724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
Study NCT04281836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive breathing awareness through use of audio and visual virtual technology aid
Description: Participants are asked to focus on their breathing while (a) listening to their breathing sounds with headphones and (b) watching the 3-D image of their lungs inhaling and exhaling in real-time using the Oculus Rift 3D virtual imaging equipment and plethysmography belt. During this time fNIRS and tQST data will be collected (more detail provided below).
Study NCT04281836 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interoceptive breathing awareness without use of audio or visual virtual reality
Description: Participants are asked to focus on their breathing. During this time fNIRS and tQST data will be collected (more detail provided below).
Study NCT04203108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: In ATG group, ATG will be intravenously infused via a central venous catheter in day -1 at a dose of 2.5mg/kg.
Study NCT04203108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
Study NCT04203108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA
Description: In both groups, CsA will be intravenously infused from day -9 and the dose was adjusted based on the concentration.
Study NCT04203108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: In both groups, MTX will be intravenously on days +1(15mg), +3(10mg) and +6(10mg).